Prostate Cancer
Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer.
March 24, 2022
Novartis Pluvicto™ (177Lu-PSMA-617) Approved by FDA as First Targeted Radioligand Therapy for Treatment of PSMA Positive mCRPC
March 23, 2022
Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men.
March 23, 2022
Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion.
March 23, 2022
Exosomal LINC01213 Plays a Role in the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manners.
March 23, 2022
PSMA-Targeting TGFβ-Insensitive Armored CAR T Cells in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Trial
March 22, 2022
Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer.
March 22, 2022